DURHAM, North Carolina and
NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Dance
Biopharm Holdings, Inc., a clinical-stage company reimagining the
treatment of chronic diseases with inhaled therapies, announced
today it has formed a strategic alliance with DarioHealth
Corp. "Dario" (Nasdaq: DRIO), a leading, global digital
therapeutics company, to expand access to a personalized digital
health management platform for patients with chronic diseases.
Under the terms of the agreement, Dance Biopharm will integrate its
gentle mist smart inhaler into DarioHealth's digital therapeutics
platform to provide patients automated, real-time treatment data
through an advanced mobile application. Dario will immediately
start the design of the integrated solution for Dance to
accommodate clinical trials and, upon regulatory approval, any
marketed solutions.
Dance Biopharm's smart inhaler paired with proprietary gentle
mist biologic formulations allows for optimal and precise delivery
of therapies through the lungs. The vibrating mesh within the
device facilitates the transmission of a soft mist that allows for
a lung deposition 2-4 times higher than conventional inhalers. In
clinical trials, the device delivered a gentle mist formulation of
human insulin with a faster drug onset and comparable duration to
subcutaneous delivery of a rapid insulin (Humalog) in patients with
type 2 diabetes (T2D). Dance is also advancing a convenient
inhalable pre-meal GLP-1 receptor agonist to improve postprandial
glucose control in T2D patients.
Dario's digital therapeutics platform combines data analytics,
high-quality software and personalized coaching to empower
individuals with information to make healthy behavioral changes.
The user-centric platform is comprised of MyDario™, a
mobile application that is data-driven, with an all-in-one blood
glucose monitoring system and an optional connected blood pressure
monitoring system. It is complemented by DarioEngage™,
a healthcare solutions platform for health and wellness providers
to customize and integrate a patient's data into their care
continuum.
"We are excited to partner with DarioHealth in empowering
patients to take charge of their chronic illness. This platform is
well established in the digital therapeutics space and has
demonstrated positive behavior change in patients with chronic
diseases through its user-centered approach," said Anne Whitaker, chief executive officer of Dance
Biopharm. "We share a similar goal of adapting our platforms to
chronic diseases beyond diabetes. Dance Biopharm is exploring
opportunities to pair the smart inhaler with gentle mist biologic
formulations beyond insulin. Our initial focus is on rare and
severe diseases in the endocrinology, respiratory, and
cardiovascular space, where our platform and expertise present a
unique opportunity to achieve better treatment efficiency."
"Diabetes is a complex chronic condition that evolves over
time, making real-time, streamed patient data essential
to care," said Erez Raphael, chief executive
officer of DarioHealth. "Through this strategic alliance, we
are excited to expand the potential for
our patient-centered, diabetes care and management solutions
by integrating the smart inhaler, optimized to deliver a
gentle mist formulation of insulin through the
lungs, into our digital therapeutics platform, which
includes blood glucose and blood pressure monitoring
systems. Our goal is to place control of diabetes
management directly into the hands of our users and, pending
completion of clinical trials and regulatory approval, we believe
that this alliance will help advance that critical objective."
About Dance Biopharm
Dance Biopharm is a
clinical-stage company reimagining the treatment of chronic
diseases with inhaled therapies. Our gentle mist inhaler is
designed with smart technology to optimize the precise delivery of
biologic therapies through the lungs. We are building a diverse
pipeline of inhaled biologic products with initial focus on rare
and severe diseases in the endocrinology, respiratory and
cardiovascular space, where our platform and expertise present a
unique opportunity to achieve better treatment efficiency. We have
initiated development programs in glucagon-like peptide-1 (GLP-1),
parathyroid hormone (PTH) and human growth hormone (HGH).
For more information, visit: https://www.dancebiopharm.com.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq:
DRIO) is a leading, global digital therapeutics
company revolutionizing the way people with chronic conditions
manage their health. By delivering evidence-based interventions
that are driven by data, high-quality software and coaching, we
empower individuals to make healthy adjustments to their daily
lifestyle choices to improve their overall health. Our
cross-functional team operates at the intersection of life
sciences, behavioral science and software technology to deliver
highly engaging therapeutic interventions. Dario is one of the
highest-rated diabetes solutions in the market, and its
user-centric MyDario™ mobile app is loved by tens of
thousands of consumers around the globe. DarioHealth is rapidly
moving into new chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions, please go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company discusses
the integration of Dance Biopharm's gentle mist inhaler with its
digital platform, that Dario will immediately start the design of
the integrated solution for Dance to accommodate clinical trials
and, upon regulatory approval, any marketed solutionsand the belief
that Dario's alliance with Dance, pending completion of clinical
trials and regulatory approval, will help advance the critical
objective of placing control of diabetes management directly into
the hands of its users, it is using forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario)
may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1.347.767.4220
Media Inquiries:
Catherine
Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1.917.330.8934
Gloria Gasaatura
LifeSci Public Relations
ggasaatura@lifescipublicrelations.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dance-biopharm-partners-with-dariohealth-to-expand-access-to-digital-therapeutics-platform-for-patients-with-chronic-diseases-300915954.html
SOURCE DarioHealth Corp.; Dance Biopharm Holdings, Inc.